Venous thromboembolism in COVID-19: Are women different?

摘要: The epidemiological data suggests predominant male prevalence, morbidity and mortality with SARS COVID-2. Similarly, venous thromboembolic (VTE) events have a sex predilection variant mechanisms involving angiotensin-converting enzyme 2 (ACE-2) expression pathways in women. COVID-19 could directly affect or it be an indirect action of the disease via critical ailment hypoxemia, hemostatic abnormalities might underlying VTE patient baseline risk factor profile. diagnosis COVID scenario has issues prone positioned patient, exposure health workers minimal therapeutic benefits critically ill acute respiratory distress syndrome (ARDS). Anticoagulation low-molecular weight heparin (LMWH) can chosen over unfractionated (UFH) less monitoring requirements thereby low to healthcare workers. Variant guidelines for thromboprophylaxis (in hospital/extended postdischarge) come up, stating anticoagulant administration, according profile biomarkers. Catheter-directed interventions should reserved only life-threatening situations. In women, hormonal milieu (for e.g., 17 β-estradiol) influence occurrence favorable ACE polymorphisms events. management strategies female would more similar males. Combined oral contraceptives (COC) estrogen replacement therapies (ERT) may curtailed positive patients, given their thrombogenic potential. Pregnancy postpartum state need prophylaxis all presence favoring VTE. Also, when indicated continued women normal menstrual cycle. Bleeding risks specific (menorrhagia secondary dysfunctional uterine bleeding [DUB], fibroids, adnexal malignancies masses, hypothyroidism, etc.) weighed while taking decision anticoagulation regimen.